The Weekly Recap 6/20/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

 In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $17M in new funds, achieve regulatory clearances, appoint new executives, and much more on the road to LSI Europe ’25 in London (September 7–11).

Adialante

Received a $1.18M National Science Foundation SBIR Phase II award to advance the development of its compact, silent, and low-cost MRI technology. The funding brings Adialante’s total raised to nearly $3M as the team works to expand access to high-quality medical imaging worldwide.

Asabys Partners

Promoted Maite Malet and Isabel Jiménez Bernal to Principal in recognition of their leadership and impact across the firm’s healthcare investment strategy. Asabys continues to strengthen its position in health-tech and biopharma by advancing transformative technologies alongside top industry talent.

Berkshire Biomedical

Was awarded Phase I of a two-phase Fast-Track SBIR grant from the National Institutes of Health to evaluate its COPA™ System for take-home methadone management. The grant, totaling up to $2.9M, will support clinical studies aimed at improving treatment retention for patients with opioid use disorder.

Day Zero Diagnostics

Will be acquired by bioMérieux to expand next-gen sequencing capabilities in infectious disease diagnostics. The deal strengthens bioMérieux’s R&D pipeline with rapid, sequencing-based tools to accelerate pathogen ID and resistance profiling — critical for managing sepsis and other life-threatening infections.

EBR Systems

Raised an additional $13M through an oversubscribed security purchase plan to support the commercialization of its WiSE CRT leadless pacing system. Combined with a recent $36.1M institutional placement, the total $49.1M in new funding will back limited market release in 2025 and full commercial distribution in 2026.

FineHeart

Received ANSM authorization to begin a first-in-human clinical trial in France evaluating FlowMakerⓇ, its fully implantable cardiac output accelerator for advanced heart failure. The study marks a major milestone toward clinical validation of this minimally invasive, pulsatile LVAD alternative designed to preserve native cardiac function.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-62025-lsi-alumni-achievements-driving-medtech-and-healthtech-forward

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more